vs

Side-by-side financial comparison of CG Oncology, Inc. (CGON) and REZOLVE AI PLC (RZLV). Click either name above to swap in a different company.

CG Oncology, Inc. is the larger business by last-quarter revenue ($2.3M vs $1.2M, roughly 1.9× REZOLVE AI PLC). REZOLVE AI PLC runs the higher net margin — -1078.8% vs -1779.0%, a 700.2% gap on every dollar of revenue.

CG Oncology, Inc. is a clinical-stage biotechnology company focused on developing innovative targeted immunotherapies for urological cancers including non-muscle invasive bladder cancer. It primarily operates in the U.S. market, advancing pipeline candidates to address unmet medical needs for patients with limited treatment options.

REZOLVE AI PLC is a UK-based technology firm developing AI-powered mobile engagement and instant transaction platforms. Its solutions let consumers complete purchases directly from audio, video, and print content, serving retail, consumer goods, and media clients across Europe, North America, and select APAC markets.

CGON vs RZLV — Head-to-Head

Bigger by revenue
CGON
CGON
1.9× larger
CGON
$2.3M
$1.2M
RZLV
Higher net margin
RZLV
RZLV
700.2% more per $
RZLV
-1078.8%
-1779.0%
CGON

Income Statement — Q4 FY2025 vs Q2 FY2025

Metric
CGON
CGON
RZLV
RZLV
Revenue
$2.3M
$1.2M
Net Profit
$-41.3M
$-13.0M
Gross Margin
Operating Margin
-2097.3%
-808.4%
Net Margin
-1779.0%
-1078.8%
Revenue YoY
409.2%
Net Profit YoY
-29.9%
EPS (diluted)
$-0.52

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CGON
CGON
RZLV
RZLV
Q4 25
$2.3M
Q3 25
$1.7M
Q2 25
$0
$1.2M
Q4 24
$456.0K
Q1 24
$529.0K
Net Profit
CGON
CGON
RZLV
RZLV
Q4 25
$-41.3M
Q3 25
$-43.8M
Q2 25
$-41.4M
$-13.0M
Q4 24
$-31.8M
Q1 24
$-16.9M
Operating Margin
CGON
CGON
RZLV
RZLV
Q4 25
-2097.3%
Q3 25
-3069.0%
Q2 25
-808.4%
Q4 24
-8344.1%
Q1 24
-4247.4%
Net Margin
CGON
CGON
RZLV
RZLV
Q4 25
-1779.0%
Q3 25
-2629.5%
Q2 25
-1078.8%
Q4 24
-6973.7%
Q1 24
-3200.8%
EPS (diluted)
CGON
CGON
RZLV
RZLV
Q4 25
$-0.52
Q3 25
$-0.57
Q2 25
$-0.54
Q4 24
$-0.47
Q1 24
$-0.36

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CGON
CGON
RZLV
RZLV
Cash + ST InvestmentsLiquidity on hand
$742.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$752.6M
$-14.3M
Total Assets
$791.6M
$80.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CGON
CGON
RZLV
RZLV
Q4 25
$742.2M
Q3 25
$680.3M
Q2 25
$661.1M
Q4 24
$742.0M
Q1 24
$566.5M
Stockholders' Equity
CGON
CGON
RZLV
RZLV
Q4 25
$752.6M
Q3 25
$687.6M
Q2 25
$670.4M
$-14.3M
Q4 24
$733.4M
Q1 24
$568.9M
Total Assets
CGON
CGON
RZLV
RZLV
Q4 25
$791.6M
Q3 25
$729.9M
Q2 25
$701.4M
$80.1M
Q4 24
$754.8M
Q1 24
$579.1M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CGON
CGON
RZLV
RZLV
Operating Cash FlowLast quarter
$-36.2M
$-4.9M
Free Cash FlowOCF − Capex
$-36.2M
FCF MarginFCF / Revenue
-1560.0%
Capex IntensityCapex / Revenue
0.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-124.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CGON
CGON
RZLV
RZLV
Q4 25
$-36.2M
Q3 25
$-38.9M
Q2 25
$-28.0M
$-4.9M
Q4 24
$-20.7M
Q1 24
$-26.0M
Free Cash Flow
CGON
CGON
RZLV
RZLV
Q4 25
$-36.2M
Q3 25
$-39.0M
Q2 25
$-28.0M
Q4 24
$-20.9M
Q1 24
$-26.0M
FCF Margin
CGON
CGON
RZLV
RZLV
Q4 25
-1560.0%
Q3 25
-2340.4%
Q2 25
Q4 24
-4577.0%
Q1 24
-4919.5%
Capex Intensity
CGON
CGON
RZLV
RZLV
Q4 25
0.3%
Q3 25
5.8%
Q2 25
Q4 24
45.8%
Q1 24
2.3%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons